Agios Pharmaceuticals, Inc.
AGIO
$33.50
$0.912.79%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 115.68% | 3.90% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 115.68% | 3.90% | |||
| Cost of Revenue | 25.81% | -8.30% | |||
| Gross Profit | 4.40% | 11.79% | |||
| SG&A Expenses | 6.71% | -6.41% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.75% | -7.61% | |||
| Operating Income | -0.48% | 9.50% | |||
| Income Before Tax | -1.61% | 9.12% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1.61% | 8.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.61% | 8.26% | |||
| EBIT | -0.48% | 9.50% | |||
| EBITDA | -0.50% | 9.68% | |||
| EPS Basic | -0.40% | 8.94% | |||
| Normalized Basic EPS | -0.40% | 9.79% | |||
| EPS Diluted | -0.40% | 8.94% | |||
| Normalized Diluted EPS | -0.40% | 9.79% | |||
| Average Basic Shares Outstanding | 1.20% | 0.74% | |||
| Average Diluted Shares Outstanding | 1.20% | 0.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||